HOME | Alphawatch

top of page

Stock Exchange

ADA Conference Highlights GLP-1 Data and Continued Weight Loss Impacts

ADA Conference Highlights GLP-1 Data and Continued Weight Loss Impacts

ADA Conference Highlights GLP-1 Data and Continued Weight Loss Impacts

Jonathan Poyer

Jun 231 min read

June 2025 Riffin' on Real Estate

June 2025 Riffin' on Real Estate

June 2025 Riffin' on Real Estate

Jonathan Poyer

Jun 111 min read

Looking At Palantir Technologies (PLTR) and its +74.24% Stock Rise into June

Looking At Palantir Technologies (PLTR) and its +74.24% Stock Rise into June

Looking At Palantir Technologies (PLTR) and its +74.24% Stock Rise into June

Jonathan Poyer

Jun 62 min read

Sanofi with a $9.1B Acquisition of Blueprint & Cancer Conference Shows Successes for Diagnostics, Therapy, and Treatments

Sanofi with a $9.1B Acquisition of Blueprint & Cancer Conference Shows Successes for Diagnostics, Therapy, and Treatments

Sanofi with a $9.1B Acquisition of Blueprint & Cancer Conference Shows Successes for Diagnostics, Therapy, and Treatments

Jonathan Poyer

Jun 42 min read

The Doctor is IN | May 2025

The Doctor is IN | May 2025

The Doctor is IN | May 2025

Jonathan Poyer

May 161 min read

Where Are the Biotech IPOs and Deals?

Where Are the Biotech IPOs and Deals?

Where Are the Biotech IPOs and Deals?

Jonathan Poyer

May 161 min read

Commerical Aerospace Ideas and Why It is an Interesting Mid- and Long-Term Investing Opportunity

Commerical Aerospace Ideas and Why It is an Interesting Mid- and Long-Term Investing Opportunity

Commerical Aerospace Ideas and Why It is an Interesting Mid- and Long-Term Investing Opportunity

Jonathan Poyer

May 124 min read

Novartis to Acquire Regulus Therapeutics for $1.7B

Novartis to Acquire Regulus Therapeutics for $1.7B

Novartis to Acquire Regulus Therapeutics for $1.7B

Jonathan Poyer

Apr 301 min read

Following the Trend Following Trend...

Following the Trend Following Trend...

Following the Trend Following Trend...

Jonathan Poyer

Apr 252 min read

The Doctor is IN | April 2025

The Doctor is IN | April 2025

The Doctor is IN | April 2025

Jonathan Poyer

Apr 221 min read

Merck's Announcement of Successful Phase 3 Trial of Subcutaneous Keytruda Progresses Towards FDA Submission

Merck's Announcement of Successful Phase 3 Trial of Subcutaneous Keytruda Progresses Towards FDA Submission

Merck's Announcement of Successful Phase 3 Trial of Subcutaneous Keytruda Progresses Towards FDA Submission

Jonathan Poyer

Mar 312 min read

AbbVie and the Influence of AI on Research

AbbVie and the Influence of AI on Research

AbbVie and the Influence of AI on Research

Jonathan Poyer

Mar 241 min read

bottom of page